|
시장보고서
상품코드
1869928
세계의 RNA 분석 시장 - 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 사용자별, 지역별 및 부문 예측RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR, Microarray, Sequencing), By Application, By End Use, By Region, And Segment Forecasts |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
RNA 분석 시장 요약
세계의 RNA 분석 시장 규모는 2024년에 86억 2,000만 달러로 추정되었으며, 2033년까지 236억 5,000만 달러에 이를 것으로 예측됩니다.
2025년부터 2033년까지 연평균 복합 성장률(CAGR) 12.55%로 성장할 전망입니다. 이러한 성장은 정밀의료에서의 전사체 연구 수요 증가, 차세대 시퀀싱(NGS) 기술의 진보, 질병 진단 및 신약개발에서 RNA 바이오마커 응용 확대에 의해 견인되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장의 변수, 동향, 범위
- 시장 계통 전망
- 상위 시장 전망
- 관련/보조시장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 업계 분석 툴
- Porter's Five Forces 분석
- PESTEL 분석
제4장 제품 비즈니스 분석
- 제품 부문 대시보드
- 세계의 RNA 분석 시장 : 제품별 변동 분석
- 세계의 RNS 분석 시장 : 규모와 동향 분석(제품별, 2021-2033년)
- 기기
- 키트 및 시약
- miRNA 및 siRNA
- 역전사효소 및 RT-PCR
- RNA 추출 및 정제
- RNA 간섭
- 기타
- 서비스
제5장 기술 비즈니스 분석
- 기술 부문 대시보드
- 세계의 RNA 분석 시장 : 기술별 변동 분석
- 세계의 RNS 분석 시장 : 규모와 동향 분석(기술별, 2021-2033년)
- 실시간 PCR(qPCR)
- 마이크로어레이
- 시퀀싱
- 기타
제6장 용도별 비즈니스 분석
- 용도 부문 대시보드
- 세계의 RNA 분석 시장 : 용도? 변동 분석
- 세계의 RNS 분석 시장 : 규모와 동향 분석(용도별, 2021-2033년)
- RNA 발현 아틀라스 구축
- 후성 유전학
- 감염증 및 병인
- 선택적 RNA 스플라이싱
- RNA 구조 및 분자 동역학
- RNA 치료제 개발 및 제공
- 기타
제7장 최종 사용자별 비즈니스 분석
- 최종 사용자 부문 대시보드
- 세계의 RNA 분석 시장 : 최종 사용자별 변동 분석
- 세계의 RNS 분석 시장 : 규모와 동향 분석(최종 용도별, 2021-2033년)
- 정부기관 및 학술센터
- 제약 및 바이오테크놀러지 기업
- 병원 및 클리닉
- 수탁연구기관(CRO)
제8장 지역 비즈니스 분석
- RNA 분석 시장 점유율(지역별), 2022년 및 2033년
- 북미
- 북미 RNA 분석 시장, 2021-2033년
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽의 RNA 분석 시장, 2021-2033년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 아시아태평양의 RNA 분석 시장, 2021-2033년
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 라틴아메리카의 RNA 분석 시장, 2021-2033년
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 중동 및 아프리카의 RNA 분석 시장, 2021-2033년
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제9장 경쟁 구도
- 기업 분류
- 전략 매핑
- 기업 포지셔닝 분석, 2024년
- 기업 프로파일
- Agilent Technologies, Inc
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Pacific Bioscience of California, Inc.;
- Affymetrix, Inc.
- Danaher
- Promega
RNA Analysis Market Summary
The global RNA analysis market size was estimated at USD 8.62 billion in 2024 and is projected to reach USD 23.65 billion by 2033, growing at a CAGR of 12.55% from 2025 to 2033. This growth is driven by the rising demand for transcriptomic studies in precision medicine, advancements in next-generation sequencing (NGS) technologies, and increasing applications of RNA biomarkers in disease diagnostics and drug discovery.
Global RNA Analysis Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global RNA analysis market on the basis of product, technology, application, end use, and region.
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Kits & Reagents
- miRNA & siRNA
- Reverse Transcriptases & RT-PCR
- RNA Extraction & Purification
- RNA Interference
- Others
- Services
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Real Time-PCR (qPCR)
- Microarray
- Sequencing
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Construction of RNA expression atlas
- Epigenetics
- Infectious diseases and pathogenesis
- Alternative RNA splicing
- RNA structure and molecular dynamics
- Development and delivery of RNA therapeutics
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Government Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract research Organizations (CROs)
- Hospitals & Clinics
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Product
- 1.1.2. Technology
- 1.1.3. Application
- 1.1.4. End Use
- 1.2. Market Definitions
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Others
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Advances in sequencing technologies
- 3.2.1.2. Drug development and vaccine research
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Higher Cost of Research & Developments
- 3.2.2.2. High Costs Associated With Analysis Platforms
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
Chapter 4. Product Business Analysis
- 4.1. Product Segment Dashboard
- 4.2. Global RNA Analysis Market: Product Movement Analysis
- 4.3. Global RNS Analysis Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
- 4.5. Kits & Reagents
- 4.5.1. Kits & Reagents Market, 2021 - 2033 (USD Million)
- 4.5.2. miRNA & siRNA
- 4.5.2.1. miRNA & siRNA Market, 2021 - 2033 (USD Million)
- 4.5.3. Reverse Transcriptases & RT-PCR
- 4.5.3.1. Reverse Transcriptases & RT-PCR Market, 2021 - 2033 (USD Million)
- 4.5.4. RNA Extraction & Purification
- 4.5.4.1. RNA Extraction & Purification Market, 2021 - 2033 (USD Million)
- 4.5.5. RNA Interference
- 4.5.5.1. RNA Interference Market, 2021 - 2033 (USD Million)
- 4.5.6. Others
- 4.5.6.1. Other Kits & Reagents Market, 2021 - 2033 (USD Million)
- 4.6. Services
- 4.6.1. Services Market, 2021 - 2033 (USD Million)
Chapter 5. Technology Business Analysis
- 5.1. Technology Segment Dashboard
- 5.2. Global RNA Analysis Market: Technology Movement Analysis
- 5.3. Global RNS Analysis Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. Real Time-PCR (qPCR)
- 5.4.1. Real Time-PCR (qPCR) Market, 2021 - 2033 (USD Million)
- 5.5. Microarray
- 5.5.1. Microarray Market, 2021 - 2033 (USD Million)
- 5.6. Sequencing
- 5.6.1. Sequencing Market, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Other Technologies Market, 2021 - 2033 (USD Million)
Chapter 6. Application Business Analysis
- 6.1. Application Segment Dashboard
- 6.2. Global RNA Analysis Market: Application Movement Analysis
- 6.3. Global RNS Analysis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Construction of RNA Expression Atlas
- 6.4.1. Construction of RNA Expression Atlas Market, 2021 - 2033 (USD Million)
- 6.5. Epigenetics
- 6.5.1. Epigenetics Market, 2021 - 2033 (USD Million)
- 6.6. Infectious Diseases & Pathogenesis
- 6.6.1. Infectious Diseases & Pathogenesis Market, 2021 - 2033 (USD Million)
- 6.7. Alternative RNA Splicing
- 6.7.1. Alternative RNA Splicing Market, 2021 - 2033 (USD Million)
- 6.8. RNA Structure & Molecular Dynamics
- 6.8.1. RNA Structure & Molecular Dynamics Market, 2021 - 2033 (USD Million)
- 6.9. Development & Delivery of RNA Therapeutics
- 6.9.1. Development & Delivery of RNA Therapeutics Market, 2021 - 2033 (USD Million)
- 6.10. Others
- 6.10.1. Other Applications Market, 2021 - 2033 (USD Million)
Chapter 7. End Use Business Analysis
- 7.1. End Use Segment Dashboard
- 7.2. Global RNA Analysis Market: End Use Movement Analysis
- 7.3. Global RNS Analysis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Government Institutes & Academic Centers
- 7.4.1. Government Institutes & Academic Centers Market, 2021 - 2033 (USD Million)
- 7.5. Pharmaceutical & Biotechnology Companies
- 7.5.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
- 7.6. Hospitals & Clinics
- 7.6.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
- 7.7. Contract Research Organizations (CROs)
- 7.7.1. Contract Research Organizations (CROs) Market, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
- 8.1. RNA Analysis Market Share By Region, 2022 & 2033
- 8.2. North America
- 8.2.1. North America RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Target Disease Prevalence
- 8.2.2.3. Competitive Scenario
- 8.2.2.4. U.S. RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Target Disease Prevalence
- 8.2.3.3. Competitive Scenario
- 8.2.3.4. Canada RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Target Disease Prevalence
- 8.2.4.3. Competitive Scenario
- 8.2.4.4. Mexico RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3. Europe
- 8.3.1. Europe RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Target Disease Prevalence
- 8.3.2.3. Competitive Scenario
- 8.3.2.4. UK RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Target Disease Prevalence
- 8.3.3.3. Competitive Scenario
- 8.3.3.4. Germany RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Target Disease Prevalence
- 8.3.4.3. Competitive Scenario
- 8.3.4.4. France RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Target Disease Prevalence
- 8.3.5.3. Competitive Scenario
- 8.3.5.4. Italy RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Target Disease Prevalence
- 8.3.6.3. Competitive Scenario
- 8.3.6.4. Spain RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Target Disease Prevalence
- 8.3.7.3. Competitive Scenario
- 8.3.7.4. Denmark RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Target Disease Prevalence
- 8.3.8.3. Competitive Scenario
- 8.3.8.4. Sweden RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Target Disease Prevalence
- 8.3.9.3. Competitive Scenario
- 8.3.9.4. Norway RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Competitive Scenario
- 8.4.2.4. Japan RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Competitive Scenario
- 8.4.3.4. China RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Competitive Scenario
- 8.4.4.4. India RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.5. Australia
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Target Disease Prevalence
- 8.4.5.3. Competitive Scenario
- 8.4.5.4. Australia RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.6. Thailand
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Target Disease Prevalence
- 8.4.6.3. Competitive Scenario
- 8.4.6.4. Thailand RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.4.7. South Korea
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Target Disease Prevalence
- 8.4.7.3. Competitive Scenario
- 8.4.7.4. South Korea RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Competitive Scenario
- 8.5.2.4. Brazil RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Competitive Scenario
- 8.5.3.4. Argentina RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.6. MEA
- 8.6.1. MEA RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Competitive Scenario
- 8.6.2.4. South Africa RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Competitive Scenario
- 8.6.3.4. Saudi Arabia RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Competitive Scenario
- 8.6.4.4. UAE RNA Analysis Market, 2021 - 2033 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Competitive Scenario
- 8.6.5.4. Kuwait RNA Analysis Market, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Company Position Analysis, 2024
- 9.4. Company Profiles/Listing
- 9.4.1. Agilent Technologies, Inc
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. F. Hoffmann-La Roche AG
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Illumina, Inc.
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. QIAGEN
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Thermo Fisher Scientific, Inc.
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Eurofins Scientific
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. Merck KGaA
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. Bio-Rad Laboratories, Inc.
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Pacific Bioscience of California, Inc.;
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Affymetrix, Inc.
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives
- 9.4.11. Danaher
- 9.4.11.1. Overview
- 9.4.11.2. Financial Performance
- 9.4.11.3. Product Benchmarking
- 9.4.11.4. Strategic Initiatives
- 9.4.12. Promega
- 9.4.12.1. Overview
- 9.4.12.2. Financial Performance
- 9.4.12.3. Product Benchmarking
- 9.4.12.4. Strategic Initiatives
- 9.4.1. Agilent Technologies, Inc
샘플 요청 목록